wright medical group

Duncan-Williams has published a research report on Wright Medical Group (NASDAQ: WMGI) commenting on the 2Q11 release of earnings results. In the report, Duncan-Williams wrote, "WMGI reported Q2:11 revenue and adjusted EPS of $132.5 million and $0.23, below our revenue estimate of $134.9 million...

Duncan-Williams is out with its report today on Wright Medical Group (NASDAQ: WMGI), maintaining Buy. In a note to clients, Duncan-Williams writes, "We are maintaining our BUY rating and our twelve month price target of $18.50. This represents approximately 20 times our 2011 adjusted EPS estimate...

According to a recent report from Jefferies, Wright Medical Group (NASDAQ: WMGI) has given very few details on what to expect moving forward causing Jefferies to maintain a hold rating on WMGI. In the report, Jefferies said, "While the company exceeded expectations and offered slightly better...

Oppenheimer commented on Wright Medical Group (NASDAQ: WMGI), following announcement of Wright's Q1 results. In a research report published today, Oppenheimer expressed its dissatisfaction with lack of information from Wright on the compliance issues after five of its senior managers resigned...

According to J.P. Morgan, Wright Medical Group (NASDAQ: WMGI) announced Wednesday that it has concluded an internal investigation, finding “credible evidence of serious wrongdoing.” J.P. Morgan said that the company issued a written report to both the U.S. Attorney's Office (USAO) and the U.S....

J.P. Morgan is out with its report on Wright Medical Group (NASDAQ: WMGI), reiterating Neutral. In a note to clients, J.P. Morgan writes, "The Wright business model has historically targeted 100-150bps of annual operating margin expansion, but with top-line growth in the low to mid single digits,...

Summer Street has downgraded Wright Medical (NASDAQ: WMGI) from Neutral to Sell.

According to Duncan-Williams, Wright Medical Group (NASDAQ: WMGI) CEO has resigned. Duncan-Williams reported that on April 4, 2011, Mr. Henley tendered his resignation prior to a Board meeting called to discuss management's oversight of the WMGI's ongoing compliance program. “Mr. Henley's...

Jefferies maintains its rating on shares of Wright Medical Group (NASDAQ: WMGI) at Hold “and our 12-month target is $16.” “The target is the current 1.3x EV/2011 sales multiple rolled forward to 2012 forecasts,” Jefferies writes. “Risks include slower revenue growth, particularly in extremities,...

Piper Jaffray is reiterating its Overweight rating On Wright Medical Group (NASDAQ: WMGI). Piper Jaffray writes, “Q4 looked very strong, and after netting out one-timers in the quarter, it still looked strong, driven primarily by strong underlying growth in US knees and extremities. EPS was $0.25...

Piper Jaffray released its Medical Technology & Hospital Supplies update today after attending the Current Concepts in Joint Replacement meeting (CCJR). In a note to clients, Piper Jaffray writes, "We came away from the CCJR meeting with a mixed bag of feedback regarding the outlook for volume...

Piper Jaffray released its Medical Technology & Hospital Supplies update today after attending the Current Concepts in Joint Replacement meeting (CCJR). In a note to clients, Piper Jaffray writes, "We came away from the CCJR meeting with a mixed bag of feedback regarding the outlook for volume...

Wright Medical Group, Inc. (NASDAQ: WMGI) reported weak 3Q results on Thursday night, and lowered top- and bottom-line guidance for the year, J.P. Morgan reports. Sales of $121.7M (+3.4%, +3.8%cc) came in $2.4M below Street consensus and $2M below J.P. Morgan's forecast. “For 2011, we are lowering...

Piper Jaffray has published a research report for Wright Medical Group (NASDAQ: WMGI) following the removal of DOJ overhang. In the report, Piper Jaffray writes "The United States Attorney General announced a deferred prosecution agreement with Wright Medical in reference to a criminal allegation...

JP Morgan has published a research report for Wright Medical Group (NASDAQ: WMGI) and has raised the price target from $17 to $19. In the report, JP Morgan writes "Wright announced after the close on Thursday that it has entered into a Deferred Prosecution Agreement (DPA) with the U.S. Attorney's...